IMPORTANT
SAFETY
INFORMATION FULL
PRESCRIBING
INFORMATION PATIENT
INFORMATION MEDICAL
INFORMATION PATIENT
SITE

For patients stuck in a cycle of dry eye inflammation1

DON’T MAKE THEM WAIT

See how Xiidra helped deliver relief in clinical trials

Not an actual health care professional.

sticky line
Ken Jeong holding Xiidra

Not an actual health care professional.

sticky line

For patients stuck in a cycle of dry eye inflammation1

DON’T MAKE THEM WAIT

See how Xiidra helped deliver relief in clinical trials

Dry eye scale
Dry eye scale

Symptoms

Xiidra & symptoms of
dry eye disease

The effect of Xiidra on the symptoms of dry eye disease was evaluated in 4 robust clinical studies.1

Explore the data

Inferior fluorescein Corneal Staining Score (ICSS)

Inferior fluorescein Corneal Staining Score (ICSS) from 0 to 4

Signs

Xiidra & dry eye disease signs

The impact of Xiidra on the signs of dry eye disease was measured in 4 robust clinical studies.1

See the results
Inferior fluorescein Corneal Staining Score (ICSS) from 0 to 4

Safety

Xiidra safety data in clinical trails

The adverse reactions of Xiidra were studied across 5 clinical trials in patients with dry eye disease.1

Review the data
Xiidra tolerability chart

Safety

Xiidra safety data in clinical trails

The adverse reactions of Xiidra were studied across 5 clinical trials in patients with dry eye disease.1

Review the data

†In 5 clinical studies of dry eye disease with lifitegrast ophthalmic solution, 1401 patients received at least one dose of lifitegrast (1287 of which received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure. 170 patients were exposed to Xiidra for approximately 12 months.1

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.

Important Safety Information

  • Do not use Xiidra if you are allergic to any of its ingredients. Seek medical care immediately if you get any symptoms of an allergic reaction.
  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for Full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.

Important Safety Information

  • Do not use Xiidra if you are allergic to any of its ingredients. Seek medical care immediately if you get any symptoms of an allergic reaction.
  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for Full Prescribing Information.